SCHEMBL12830025

SCHEMBL12830025

O=C(Nc1csc(-c2ccc(Cl)c(F)c2F)c1C(=O)O)c1nc2ccccc2s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.47
▸ RAB9A P51151 3/20 0.47
▸ PKM P14618 3/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ NFKB1 P19838 2/20 0.47
▸ NFKB2 Q00653 2/20 0.47
▸ RELA Q04206 2/20 0.47
▸ HDAC1 Q13547 1/20 0.45
▸ MEN1 O00255 5/20 0.44
▸ KMT2A Q03164 5/20 0.44
▸ LMNA P02545 3/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ HTT P42858 2/20 0.44
▸ TDP1 Q9NUW8 2/20 0.44
▸ CNR1 P21554 1/20 0.42
▸ CNR2 P34972 1/20 0.42
▸ CRHBP P24387 2/20 0.41
▸ CRHR2 Q13324 2/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12830018 0.89 LMNA (0.48) NPC1RAB9APKMSMN1; SMN2NFKB1
SCHEMBL12830028 0.87 HDAC1 (0.48) NPC1RAB9APKMSMN1; SMN2NFKB1
SCHEMBL12830038 0.85 HDAC1 (0.50) NPC1RAB9APKMSMN1; SMN2NFKB1
SCHEMBL1907536 0.85 RAB9A (0.49) NPC1RAB9APKMSMN1; SMN2NFKB1
SCHEMBL12830021 0.83 HDAC1 (0.49) NPC1RAB9APKMSMN1; SMN2NFKB1
SCHEMBL1490266 0.82 HDAC1 (0.47) NPC1RAB9APKMSMN1; SMN2NFKB1
SCHEMBL12830024 0.82 MEN1 (0.54) NPC1RAB9APKMSMN1; SMN2NFKB1
SCHEMBL12830121 0.80 FAAH (0.38) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL12756394 0.78 PKM (0.53) NPC1RAB9APKMSMN1; SMN2NFKB1
SCHEMBL12756404 0.78 NPC1 (0.53) NPC1RAB9APKMSMN1; SMN2NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2014-02-20 — — US disclosed
WO-2011034962-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2011-03-24 — — WO disclosed
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2011-03-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 NPC1 262/4885RAB9A 1174/4885PKM 1872/4885
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 NPC1 262/4885RAB9A 1174/4885PKM 1872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback